ArticleFrontiers in medicine2026
Morphological characteristics of acquired corneal sub-epithelium hypertrophy: a case series.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Acquired Corneal Subepithelial Hypertrophy (ACSH) is a rare corneal opacity secondary to ocular surgery or trauma. It is characterized by subepithelial fibrosis, a marked male predominance, and a high risk of misdiagnosis due to non-specific slit-lamp findings. This study aimed to characterize the Methods: This retrospective single-center case series enrolled 11 patients (12 eyes) with ACSH who underwent surgical intervention at our institution between 2018 and 2022. AS-OCT imaging was performed to evaluate subepithelial fibrosis features. All specimens underwent histopathological evaluation with hematoxylin and eosin (HE), periodic acid-Schiff (PAS), and Masson trichrome staining. Immunofluorescence analysis was conducted on five specimens to assess cytokeratins (CK3, CK14), nucleoprotein (P40-ΔNp63), cytoskeletal proteins (alpha-smooth muscle actin, vimentin), and extracellular matrix components (Collagen I, Collagen IV). Primary outcomes included AS-OCT morphological characteristics from baseline to final follow-up and corresponding histopathological findings. Results: Most patients were male, and the primary presenting symptom was blurred vision. Superficial keratectomy restored corneal clarity without recurrence during follow-up. ACSH was categorized into three subtypes: paracentral patchy opacification (PPO, 41.7%), peripheral sectorial nodules (PSN, 41.7%), and central diffuse mass (CDM, 16.7%). AS-OCT revealed hyperreflective lamellar deposits between the epithelium and stroma. The maximum thickness of fibrosis was strongly correlated with corneal surface thickness ( Discussion: AS-OCT enables reliable identification of ACSH and differentiation from corneal leucoma and haze. Histopathological observations provide insights into potential pathogenic mechanisms. These findings may inform clinical strategies to prevent ACSH, such as using topical medications or contact lenses to enhance epithelial healing after anterior segment surgery or injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.